SWX:SDZPharmaceuticals
How Sandoz’s Samsung Bioepis Deal and Q1 Biosimilar Growth Will Impact Sandoz Group (SWX:SDZ) Investors
In late April 2026, Sandoz Group reported Q1 results showing 3% net sales growth at constant currency, led by 18% growth in biosimilars, while also confirming its full-year 2026 outlook for mid- to high-single-digit sales growth and core EBITDA margin expansion.
The company also announced a new partnership with Samsung Bioepis covering up to five biosimilar assets, a move that materially broadens its pipeline and reinforces its push into higher-value biologic medicines.
We’ll now examine how...